Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Karuna Therapeutics to $245 from $258 and keeps a Buy rating on the shares. The analyst updated the company’s model post the Q3 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRTX:
- Karuna Therapeutics price target lowered to $225 from $235 at RBC Capital
- Karuna Therapeutics reports Q3 EPS ($3.16), consensus ($2.74)
- Karuna Therapeutics management to meet with Piper Sandler
- Karuna Therapeutics to present new data from EMERGENT clinical program
- Karuna Therapeutics submits NDA to FDA for KarXT